Skip to main content

Advertisement

SpringerLink
Log in

Leukocytoclastic vasculitis and long-term remission in a patient with secondary AML and post-remission treatment with low-dose interleukin-2

  • Case Report
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Interleukin-2 (IL-2) has been licensed for the treatment of renal cell carcinoma and is currently being evaluated as a therapeutic agent in hematological malignancies. It is associated with a variety of side effects due to induction of a nonspecific inflammatory response. However, phenomena of autoimmunity have also been reported. Here we describe a patient with secondary acute myeloid leukemia who developed a leukocytoclastic vasculitis during long-term post-remission treatment with very low doses of IL-2.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ettinghausen SE, Puri RK, Rosenberg SA (1988) Increased vascular permeability in organs mediated by the systemic administration of lymphokine-activated killer cells and recombinant interleukin-2 in mice. J Natl Cancer Inst 80:176–188

    Google Scholar 

  2. Connor RI, Shen L, Fanger MW (1990) Evaluation of the antibody-dependent cytotoxic capabilities of individual human monocytes. Role of Fc gamma RI and Fc gamma RII and the effects of cytokines at the single cell level. J Immunol 145:1483–1489

    PubMed  Google Scholar 

  3. Gaspari AA, Lotze MT, Rosenberg SA, Stern JB, Katz SI (1987) Dermatologic changes associated with interleukin-2 administration JAMA 258:1624–1629

    PubMed  Google Scholar 

  4. Gonzalo JA, Cuende E, Ales-Martinez JE, Martinez C, Kroemer G (1992) Interleukin-2: a possible trigger of autoimmunity. Int Arch Allergy Appl Immunol 97:251–257

    Google Scholar 

  5. Hack CE, Ogilvie AC, Eisele B, Eerenberg AJ, Wagstaff J, Thijs LG (1993) Cl-inhibitor substitution therapy in septic shock and the vascular leak syndrome induced by high doses of interleukin-2. Intensive Care Med 19 Suppl1:19–28

    Google Scholar 

  6. Hundt M, Zielinska-Skowronek M, Schmidt RE (1993) Fcy receptor activation of neutrophils in cryoglobulin-induced leukocytoclastic vasculitis. Arthritis Rheum 36:974–982

    PubMed  Google Scholar 

  7. Lindemann A, Hermann F, Oster W, Mertelsmann R (1989) Lymphokine-activated killer cells. Blut 59:375–384

    PubMed  Google Scholar 

  8. Lindemann A, Brossart P, Höffken K, Flaßhove M, Voliotis D, Diehl V, Kulmburg P, Wagner H, Mertelsmann R (1993) Immunomodulatory effects of ultra-low-dose interleukin-2 in cancer patients: a phase-IB study. Cancer Immunol Immunther 37:307–315

    Google Scholar 

  9. Lindemann A, Brossart P, Höffken K, Flaßhove M, Voliotis D, Diehl V, Kulmburg P, Wagner H, Mertelsmann R (1994) Serum cytokine levels in cancer patients treated with different schedules of ultra-low-dose interleukin-2. J Immunther 15:225–230

    Google Scholar 

  10. Lotzova E, Savary CA, Herberman RB (1987) Induction of NK cell activity against fresh human leukemia in culture with interleukin-2. J Immunol 138:2718–2727

    PubMed  Google Scholar 

  11. Massarotti EM, Liu NY, Mier J, Atkins MB (1992) Chronic inflammation arthritis after treatment with high-dose IL-2 for malignancy. Am J Med 92:693–697

    PubMed  Google Scholar 

  12. Meloni G, Foa R, Vignetti M, Guarini A, Fenu S, Tosti S, Tos AG, Mandelli F (1994) Interleukin-2 may induce prolonged remission in advanced acute myelogous leukemia. Blood 84:2158–2163

    PubMed  Google Scholar 

  13. Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang AE, Schwartzentruber DJ, Aebersold P, Leitman S, Linehan WM, Seipp CA, White DE, Steinberg SM (1993) Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with adanced cancer. J Natl Cancer Inst 85:622–632

    PubMed  Google Scholar 

  14. Rump JA, Jahreis A, Schlesier M, Stecher S, Drager R, Struff WG, Peter HH (1993) Effects of interleukin-2 therapy in patients with common variable immunodeficiency (CVID). Immunodeficiency 4:37–42

    PubMed  Google Scholar 

  15. Savige JA, Chang L, Smith CL, Duggan JA (1993) Myelodyplasia, vasculitis and antineutrophil cytoplasm antibodies. Leuk Lymphoma 9:49–54

    PubMed  Google Scholar 

  16. Schifferli JA, Ng YC, Peters DK (1986) The role of complement and its receptor in the elimination of immune complexes. N Engl J Med 315:488–495

    PubMed  Google Scholar 

  17. Schorle H, Holtschke T, Hunig T, Schimpl A, Horak I (1991) Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting. Nature 352:621–624

    PubMed  Google Scholar 

  18. Smiley JD, Moore SE (1989) Immune-complex vasculitis: role of complement and IgG-Fc receptor function. Am J Med Sci 298:267–277

    PubMed  Google Scholar 

  19. Staunton MR, Megin CS, Le Bois PE, Aronson FR (1991) Life-threatening bullous skin eruptions during interleukin-2 therapy. J Natl Cancer Inst 83:56–57

    PubMed  Google Scholar 

  20. Wallance DJ, Margolin K, Waller P (1988) Fibromyalgia and interleukin-2 therapy for malignancy. Ann Intern Med 108:909

    Google Scholar 

  21. Voss SD, Hong R, Sondel PM (1994) Severe combined immunodeficiency, interleukin-2, and the IL-2 receptor: experiments of nature continue to point the way. Blood 83:626–635

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik I, University of Freiburg, Hugstetterstrasse 55, D-79106, Freiburg, Germany

    M. Engelhardt, R. Mertelsmann & A. Lindemann

  2. Department of Rheumatology and Clinical Immunology, University of Freiburg, Germany

    J. A. Rump

  3. Department of Pathology, University of Freiburg, Germany

    U. Hellerich

Authors
  1. M. Engelhardt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. A. Rump
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. U. Hellerich
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. Mertelsmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Lindemann
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Supported by the Bundesministerium für Forschung und Technologie, Förderzeichen 01GA8901/3

Rights and permissions

Reprints and permissions

About this article

Cite this article

Engelhardt, M., Rump, J.A., Hellerich, U. et al. Leukocytoclastic vasculitis and long-term remission in a patient with secondary AML and post-remission treatment with low-dose interleukin-2. Ann Hematol 70, 227–230 (1995). https://doi.org/10.1007/BF01700380

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01700380

Key words

Search

Navigation